Clinical trials: Chronic Hepatitis
Hepatitis B, Chronic
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB)…
- Trial name
- NCT01023230
- Testing
- DV-601, Entecavir
- Where
- 4 sites in Poland
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis C, Chronic, Substance Use Disorders
Linkage to Care for Persons With Hep C Infection
Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016.
- Trial name
- NCT05397067
- Testing
- Peer specialist (PS), Incentives, telehealth visits
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Carilion Clinic
Chronic Hepatitis B Virus
The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).
The investigators' research is aimed at developing more effective, finite approaches for managing individual patients with chronic hepatitis B (CHB).
- Trial name
- BeNEG-DO (NCT02845401)
- Testing
- Stop NA therapy
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- California Pacific Medical Center Research Institute
Hepatitis C Virus Infection
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
This Registry will enroll adolescent and pediatric participants who received at least one Gilead Hepatitis C Virus (HCV) direct acting antiviral (DAA) while participating in a Gilead-sponsored chronic hepatitis C clinical trial.
- Trial name
- NCT02510300
- Testing
- Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL)
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 461 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown.
- Trial name
- NCT04939441
- Testing
- Tenofovir alafenamide
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Jidong Jia
Autoimmune Hepatitis
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is characterized by chronic inflammation of the liver, interface hepatitis, hypergammaglobulinemia, and the presence of autoantibodies.
- Trial name
- NCT01661842
- Testing
- conventional plus UC-MSC treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital
Hepatitis C, Chronic, DIABETES MELLITUS Type 2
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response…
- Trial name
- HEP-C-FM (NCT01770483)
- Testing
- nitazoxanide, conventional interferon alfa, Ribavirin
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Hepatitis B, Chronic
Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B
Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration.
- Trial name
- STOP-B (NCT05328427)
- Testing
- Stopping
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- Göteborg University
Liver Failure, Acute, Hepatitis, Autoimmune
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a chronic liver disease, which is characterized by the increase of immunoglobulin G (IgG) level, the presence of auto-antibodies and a typical histology, in the absence of other liver disease.
- Conditions
- Liver Failure, Acute, Hepatitis, Autoimmune, Organ Dysfunction Scores, Risk Factors
- Trial name
- PRO-SURFASA (NCT05473403)
- Testing
- Corticosteroid therapy
- Where
- 26 sites in France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis C
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic hepatitis C genotype 1b Infection
- Trial name
- RELIF-C (NCT02865369)
- Testing
- Daclatasvir and Asunaprevir
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Sang Gyune Kim
Hepatitis B, Chronic
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
This randomized, 2 x 2 factorial, parrallel group study will compare the efficacy and safety of 48 versus 96 weeks of peginterferon alfa-2a [Pegasys], with or without entecavir, in patients with HbeAg negative chronic hepatitis…
- Trial name
- NCT01179594
- Testing
- entecavir, peginterferon alfa-2a [Pegasys]
- Sponsor
- Hoffmann-La Roche
Genotype 1 Chronic Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects.
- Trial name
- NCT00606086
- Testing
- GI-5005, Pegylated Interferon and Ribavirin
- Where
- 25 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlobeImmune
Autoimmune Hepatitis
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis
1. To evaluate the immunohistochemical expression of USP35 in cases of juvenile autoimmune hepatitis and control cases. 2. To correlate this with the level of necro-inflammation and extent of fibrosis using Massion's trichrome…
- Trial name
- NCT06896383
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Autoimmune Hepatitis
Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis
Rationale: Current standard therapy of autoimmune hepatitis consists of a combination of prednisolone and azathioprine. However, a significant proportion of patients does not respond to, or is intolerant for, azathioprine.
- Trial name
- CAMARO (NCT02900443)
- Testing
- Mycophenolate mofetil, Azathioprine
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
Chronic Hepatitis C
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
- Trial name
- NCT00749138
- Testing
- tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Bader, Ted, M.D.
Chronic Hepatitis B
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens at Week 24 in participants with chronic…
- Trial name
- NCT02862548
- Testing
- TAF, TDF, Other approved antivirals
- Where
- New Zealand
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Hepatitis, Safety and Tolerability
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened.
- Trial name
- NCT03685708
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Hepatitis C Infection, Compensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir)…
- Trial name
- TURQUOISE-II (NCT01704755)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Volunteers
- 381 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
The aim of this study is to explore the efficacy and safety of boceprevir -based triple therapy to rescue HCV genotype 1 (HCV GT1)/HBV dually infected patients refractory to previous peginterferon (PEG-IFN) plus ribavirin (RBV)…
- Trial name
- BOLERO-CB (NCT02060058)
- Testing
- Stop trial intervention for boceprevir, PEG-IFN and RBV
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital